Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.

ABSTRACT:

Purpose

A deregulated epigenome contributes to the transformed phenotype of mantle cell lymphoma (MCL). This involves activity of the polycomb repressive complex (PRC) 2, containing three core proteins, EZH2, SUZ12, and EED, in which the SET domain of EZH2 mediates the histone methyltransferase activity. We determined the effects of 3-deazaneplanocin A (DZNep), an S-adenosylhomocysteine hydrolase inhibitor, and/or pan-histone deacetylase inhibitor panobinostat (PS) on cultured and primary MCL cells.

Experimental design

Following treatment with DZNep and/or PS, apoptosis and the levels and activity of EZH2 and PRC2 proteins in cultured and primary MCL cells were determined.

Results

Treatment with DZNep depleted EZH2, SUZ12, and 3MeK27H3 in the cultured human MCL cells.

SUBMITTER: Fiskus W 

PROVIDER: S-EPMC4113119 | biostudies-literature | 2012 Nov

REPOSITORIES: biostudies-literature